Themis announced that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwide license to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform that was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry.
The licensed technology is a modified measles virus based on the viral genome sequence of the established measles vaccine strain, which has been used to immunize billions of people worldwide. The measles virus itself has innate anti-cancer properties, for example, mediating tumor cell lysis, T cell activation and specific tumor cell targeting. Furthermore, it can also be engineered to include a tumor killing payload, making it a major building block for an effective oncolytic virus immunotherapy.
Themis established a robust cGMP manufacturing process for its measles vector technology and built a broad pipeline with both proprietary and partnered infectious disease vaccine candidates. The lead program in Chikungunya is anticipated to enter Phase 3 development in the near- to medium-term. Themis believes that licensing deal with Max-Planck-Innovation GmbH will further expand its innovative technology platform to include novel oncolytic virus-based immunotherapy applications.
Themis Bioscience GmbH develops vaccines for tropical infectious diseases. It offers prophylactic vaccines from the preclinical to the early clinical phase. The company develops vaccines for Chikungunya and Zika. Themis Bioscience GmbH offers Themaxyn platform technology. The company was founded in 2009 and is based in Vienna, Austria.
Max Planck Innovation GmbH provides technology transfer from the research institutes of the Max Planck Society. It advises and supports scientists in evaluating inventions and filing patent applications; and markets patents and technologies to industry and coach founders of new companies. The company also offers licensing and spin-offs, as well as services for products, such as therapeutics, diagnostics, plant biotechnology, biotechnology methods and processes, analytics, new materials, software, and devices, sensors, and components. It provides its services for inventors and founders, as well as industries. Max Planck Innovation GmbH was formerly known as Garching Innovation AG. The company was founded in 1970 and is based in Munich, Germany.